{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-003329","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.842061+00:00","generated_at":"2026-05-17T06:40:48.861726+00:00","sec_items":["3.02","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Silexion regains Nasdaq compliance with $9.4M equity after capital raise","bullets":["Issued 450,000 shares to sponsor upon converting $1.8M of convertible note at $4.00/share; remaining $1.6M outstanding.","Shareholders' equity rose to ~$9.4M from -$0.7M at July 31, 2025, after four transactions.","Company affirms compliance with Nasdaq Capital Market equity requirement of $2.5M and expects long-term compliance.","Gross proceeds from September 2025 public offering: ~$6.0M from sale of shares/pre-funded warrants and warrants.","Warrant exercise inducement in August 2025 generated ~$1.8M gross proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-003329","json":"https://secwatch.observer/filing/0001178913-25-003329.json","markdown":"https://secwatch.observer/filing/0001178913-25-003329.md","text":"https://secwatch.observer/filing/0001178913-25-003329.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325003329/0001178913-25-003329-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325003329/zk2533784.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:40:48.861726+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"28fed5cd5c1fbb09c17c6e438809c2bb2b89c304","claim":"Silexion Therapeutics Corp issued 450,000 ordinary shares of common stock to Moringa Sponsor, LP for $1.8 million of the outstanding amount under the Amended and Restated Promissory Note.","evidence_excerpt":"On September 15, 2025, Silexion Therapeutics Corp, a Cayman Islands exempted company (“ Silexion ” or the “ Company ”) issued 450,000 ordinary shares, par value $0.0135 per share, of Silexion (“ ordinary shares ”), to Moringa Sponsor, LP (the “ Sponsor ”) upon conversion by Silexion of an aggregate of $1.8 million of the outstanding amount under the Amended and Restated Promissory Note, dated August 15, 2024, in an original principal amount of $3.4 million (the “ Sponsor Convertible Note ”), issued by Silexion to the Sponsor.","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325003329/0001178913-25-003329-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"450,000 ordinary shares"},{"label":"Purchaser","value":"Moringa Sponsor, LP"},{"label":"Consideration","value":"$1.8 million of the outstanding amount under the Amended and Restated Promissory Note"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}